Fate Therapeutics, Inc., a clinical-stage biopharma company focused on the development of programmed cellular immunotherapies for cancer and immune disorders, began IND-enabling production of FT500 at the University of Minnesota, Molecular and Cellular Therapeutics, an FDA-registered GMP facility. FT500 is a first of its kind, natural killer (NK) cell cancer immunotherapy generated from a self-renewing clonal master pluripotent cell line (MPCL). It was created using the company’s iPSC product...